All Posts Tagged With: "biotech"
Healthcare In a State of Flux
Long thought to be an industry that could be banked on for stability by defensive investors during periods of turmoil, the healthcare industry should now be carefully navigated.
Two sectors within the industry that are worth noting right now are healthcare…
27Oct2008 | Oxbury Research | 0 comments | ContinuedInvesting in Biotech: How to Profit from the 3 “Phases” of Clinical Trials
When it comes to investing in biotech, Marc Lichtenfeld is one of the smartest analysts in the field. He’s a pro at finding companies in this group that consistently outperform. But more importantly, I trust his opinion. Today, he’s showing…
2Sep2008 | Investment U | 0 comments | ContinuedThe Start to the Convergence Revolution
Nanotech/Biotech Convergence and Opportunities Accelerating
Not that long ago, the media were full of warnings that Big Pharma was running out of steam. Patents were expiring, and not enough new candidates were in the pipeline to keep them profitable.
We don’t have…
25Jul2008 | The Penny Sleuth | 0 comments | ContinuedSmall-Cap Vaccines
Small Wonders
The media have dubbed it “the new age of epidemics.” From SARS to cancer, diabetes to the flu, we live in a world of increasingly powerful germs and diseases.
Drug companies large and small have renewed their interest in one…
24Jul2008 | Whiskey and Gunpowder | 0 comments | ContinuedSwitzerland’s Roche Makes $43.7 Billion Offer for U.S. Biotech Pioneer Genentech
Roche Holding Ltd. (OTC ADR: RHHBY) yesterday (Monday) announced a $43.7 billion offer for the 44% of Genentech Inc. (DNA) it doesn’t already own.
Switzerland-based Roche’s $89 per share cash offer is almost a 9% premium over San Francisco-based Genentech’s Friday closing price.…
22Jul2008 | Money Morning | 0 comments | ContinuedBiotech Stocks: Opportunities abound for Osiris Therapeutics (OSIR:NASDAQ)
‘This Maryland-based biotechnology firm develops treatments for conditions as varied as Crohn’s disease, knee arthritis, tissue damage, life-threatening Graft-versus-host disease and acute radiation syndrome.’ – Laura Cadden
Osiris Therapeutics, Inc. creates therapeutic drugs from human mesenchymal stem cells (MSCs) retrieved from bone…
27May2008 | Laura Cadden | 0 comments | ContinuedProfit Opportunity: A diamond in a mud pit
This is a very scary period of time for investors. Just when they think they have the market figured out, it turns out to be a head fake and the market changes track.
If not careful, this market could become more…
4Apr2008 | Andrew Snyder | 0 comments | Continued
-
-
Sponsors
Loading ...
